Mouse epiblast stem cells (EpiSCs) are cultured with FGF2 and Activin A, like human embryonic stem cells (hESCs), but the action of the associated pathways in EpiSCs has not been well characterized. Here, we show that activation of the Activin pathway promotes self-renewal of EpiSCs via direct activation of Nanog, whereas inhibition of this pathway induces neuroectodermal differentiation, like in hESCs. In contrast, the different roles of FGF signaling appear to be only partially conserved in the mouse. Our data suggest that FGF2 fails to cooperate with SMAD2/3 signaling in actively promoting EpiSC self-renewal through Nanog, in contrast to its role in hESCs. Rather, FGF appears to stabilize the epiblast state by dual inhibition of differentiation to neuroectoderm and of media-induced reversion to a mouse embryonic stem cell-like state. Our data extend the current model of cell fate decisions concerning EpiSCs by clarifying the distinct roles played by FGF signaling.
INTRODUCTION
hESCs, like mouse embryonic stem cells (mESCs), are derived from the inner cell mass (ICM) tissue of preimplantation embryos. Hence, both share a number of cellular characteristics, such as pluripotency and self-renewal capability. The latter is controlled by a network of transcription factors that serves to maintain the undifferentiated ESC state, in part by promoting the expression of ESC-specific genes and suppressing that of differentiationspecific ones (Boyer et al., 2005; Chen et al., 2008; Kim et al., 2008) . The transcription factors OCT4, NANOG, and SOX2 are of central importance in both human and mouse ESCs, because silencing of their gene expression usually has deleterious effects on the self-renewal machinery, i.e., leads to cellular differentiation (Fong et However, hESCs and mESCs differ markedly in their responses to signaling pathways that support self-renewal (see Figure S1 available online). mESCs require LIF/STAT3 signaling for self-renewal and benefit from mimicking WNT/b-catenin signaling with small-molecule GSK3b inhibitors (Niwa et al., 2009; Sato et al., 2004) . The FGF/ERK cascade plays a role in the differentiation of mESCs, as evidenced, for example, by the inability of Erk2 À/À ESCs to differentiate along somatic cell lineages (Kunath et al., 2007) . Thus, mESCs can be maintained in culture in a highly undifferentiated state by manipulating these pathways: i.e., by adding LIF, a GSK3b inhibitor, and a MEK inhibitor to inactivate FGF/ERK signaling ( Figure S1 ; Guo et al., 2009; Ying et al., 2008) .
In contrast, hESCs do not respond to LIF (Dahé ron et al., 2004) . WNT/b-catenin signaling induces hESC differentiation under chemically defined conditions (Sumi et al., 2008) , and FGF/ERK signaling promotes self-renewal. Virtually all hESC media described to date contain FGF2 (e.g., Dvorak et al., 2005; Furue et al., 2008; Levenstein et al., 2006; Xu et al., 2005; Yao et al., 2006) . However, FGF2 supplementation has been associated with pleiotropic-positive effects: impeding spontaneous differentiation, increasing hESC proliferation, enhancing attachment/survival, inhibiting earliest neural induction, and, more precisely, moderately stimulating NANOG gene expression (Eiselleova et al., 2009; Greber et al., 2007 Greber et al., , 2008 Li et al., 2007; Ludwig et al., 2006; Wang et al., 2009) . Furthermore, FGF2 also exerts its effects through indirect mechanisms, via cells cocultured with hESCs (Bendall et al., 2007; Greber et al., 2007) . For instance, FGF2 may stimulate mouse embryonic fibroblasts (MEFs)-which are frequently used as feeder layers-to secrete Activin A (ActA; Greber et al., 2007) . ActA belongs to the TGF-b family of ligands and promotes activation of the SMAD2/3 transcription factors, which is considered beneficial for hESC self-renewal ( Figure S1 ; James et al., 2005; Vallier et al., 2005) . SMAD2/3 has been found to bind to the NANOG promoter and thereby activate NANOG gene transcription, establishing a direct link between a signaling pathway and the selfrenewal network in hESCs (Greber et al., 2008; Xu et al., 2008) .
EpiSCs are derived from the pluripotent epiblast tissue of early postimplantation mouse embryos (Brons et al., 2007; Tesar et al., 2007) . These cells express Oct4, Nanog, and Sox2 and exhibit features of pluripotency both in vitro and in teratoma assays. Moreover, they display flattened colony morphology similar to that of hESCs. Furthermore, they are derived and maintained under conditions that also support hESC self-renewalwith FGF2 on inactivated MEFs or with FGF2 and ActA under feeder-free conditions. These findings suggest that human ESCs may rather correspond to cells of a postimplantation/ pregastrulation stage of mammalian development. Indeed, pathways driving directed hESC differentiation appear to be consistent with this concept (Murry and Keller, 2008) .
However, in addition to their blastocyst origin, hESCs share several molecular features with mESCs, but not with EpiSCs. These include the expression of the ICM marker gene REX1 as well as the lack of expression of the epiblast-specific FGF5 gene (Adjaye et al., 2005; Darr et al., 2006; Pelton et al., 2002) . Moreover, the transcription factor KLF4 has been shown to be vital for the direct reprogramming of human somatic cells to an ESC-like state, and KLF4 is expressed and functional in hESCs (Chan et al., 2009; Nakagawa et al., 2008) . Klf4 is also expressed in mESCs but almost completely silenced in EpiSCs, and Klf4 overexpression has been shown to result in the reversion of EpiSCs back to an ESC-like state .
The mouse is the most important model organism for generating hypotheses about how to maintain and differentiate human ESCs. And, because EpiSCs may represent an important link between human ESCs and the mouse embryo, significant information can be gained by better defining the relationship between hESCs and EpiSCs. To this end, we have characterized the roles of SMAD2/3 and FGF/ERK signaling in EpiSCs. We find that SMAD2/3 signaling directly controls Nanog expression in EpiSCs, as in hESCs, despite the low conservation of SMAD2/ 3/4 binding sites in the mouse Nanog promoter. Surprisingly, with respect to FGF/ERK signaling, FGF2 fails to actively support self-renewal in EpiSCs via Nanog expression, in contrast to its role in hESCs. Rather, it supports the EpiSC state by inhibiting lineage commitment. On the one hand, FGF2 appears to inhibit neural induction; on the other hand, it helps impede reversion to an ESC-like state by suppressing Klf2.
RESULTS

Generation of Epiblast Stem Cells
EpiSCs were established from day 5.5 hybrid embryos under hESC culture conditions (GOF18-GFP 3 129Sv; Amit et al., 2004; Yoshimizu et al., 1999) . One karyotypically normal line, termed E3, was used for most further investigations ( Figure 1A ). E3 expressed the pluripotency genes Oct4, Nanog, and Sox2 at levels comparable to those in mouse ESCs. As expected, however, the epiblast marker Fgf5 was strongly upregulated, whereas the mESC-specific genes Rex1, Esrrb, Klf4, and others were expressed at much lower levels than in mESCs ( Figure 1B ). Upon injection into immunocompromised mice, the E3 cells readily gave rise to teratomas containing differentiated derivatives of all three germ layers ( Figure 1C) . Furthermore, the cells preferentially used the epiblast-specific proximal enhancer to drive Oct4 expression, exhibited insensitivity to inhibition of the LIF/STAT3 pathway, yet displayed sensitivity to suppression of SMAD2/3 signaling (see below; Tesar et al., 2007; Yeom et al., 1996) . Finally, global gene expression analysis revealed that E3 cells were very similar to EpiSCs that had been independently derived in a different laboratory ( Figure 1D ; Table S1 , line T9). We therefore conclude that the E3 cells are bona fide EpiSCs.
Nanog Is a Direct Target of SMAD2/3 Signaling in EpiSCs Although SMAD2/3 directly regulates NANOG expression in human ESCs (Greber et al., 2008; Vallier et al., 2009a; Xu et al., 2008) , most (putative) SMAD2/3/4 binding sites are not conserved in the mouse ( Figure S2D ). We therefore sought to investigate this point in EpiSCs. We first attempted to grow EpiSCs under feeder-free conditions in MEF-conditioned medium that contained physiological levels of ActA to stimulate SMAD2/3 signaling ( Figures S1 and S2A ). E3 EpiSCs were found to grow robustly as flat colonies, with minimal differentiation (Figure 2A ). Oct4, Nanog, and Sox2 levels were comparable to those in cultures on MEFs. However, when SMAD2/3 signaling was blocked for 12 hr, by treatment with SB431542 (SB; Figure S1 ), NANOG, but not OCT4 or SOX2, protein levels decreased substantially ( Figure 2B ). To assess whether Nanog expression is supported in a paracrine manner by ActA, EpiSCs were transferred to defined medium at a low density and exposed to varying doses of ActA. Indeed, the Nanog expression level correlated with the ActA concentration in the medium ( Figure 2C) .
A direct connection between the activity of a signaling pathway and target gene expression can be elucidated by assessing corresponding transcriptional responses over the short term. In EpiSCs, Nanog expression was found to drop by 70% within 3 hr of treatment with SB. Upon restimulation with ActA, Nanog expression was immediately induced. Oct4, however, exhibited almost no short-term response ( Figure 2D ). A very similar pattern was obtained with two other EpiSC lines ( Figure S2B ). Moreover, Nanog expression in mouse ESCs was unaffected by SB treatment, suggesting that sensitivity to SMAD2/3 inhibition is a defining feature of EpiSCs ( Figure S2C ). The shortterm induction of Nanog in SB-starved EpiSCs did not require (E) RT-qPCR of SB-starved and restimulated samples. Cycloheximide was added for 2 hr to both the control and restimulated samples. Bars reflect normalization error. (F) ChIP-qPCR with two primer pairs spanning a putative SMAD2/3 binding site in the Nanog promoter, as illustrated in Figure S2D . Left: EpiSCs harvested under SMAD2/3-stimulating conditions. Right: Cells pretreated for 2 hr with SB. Bars reflect normalization error. (G) Luciferase assay with wild-type and mutated Nanog promoter fragments illustrated in Figure S2D . Note that SB treatment of EpiSCs significantly reduced activity only when the putative SMAD2/3 binding site was intact. Bars: SEM between biological duplicates. new protein synthesis because it also occurred in the presence of cycloheximide ( Figure 2E ). We therefore performed ChIPqPCR with a phospho-SMAD2/3 antibody to determine whether control of Nanog expression is mediated by direct Nanog promoter occupancy. Two amplicons spanning the only putative SMAD2/3/4 binding site in the mouse Nanog promoter showed enrichment over input and over a downstream negative control region under SMAD2/3-activating conditions ( Figure 2F; Figure S2D) . Importantly, these signals were abolished under SMAD2/3-inactivating conditions, confirming their specificity ( Figure 2F ). To assess the functionality of the putative SMAD2/ 3/4 binding site, wild-type and mutated Nanog promoter fragments ( Figure S2D ) driving luciferase expression were transfected into EpiSCs under SMAD2/3-activating and -inactivating conditions. As expected, the wild-type construct exhibited significantly higher activity than the mutated one under SMAD2/3-activating conditions, but the difference in activity became insignificant under inactivating conditions, suggesting that the site is indeed SMAD2/3 responsive ( Figure 2G ).
When passaged as clumps, at a sufficient density, E3 EpiSCs actually did not require ActA supplementation to remain in an undifferentiated state. Only when cells were plated as smaller clumps, at a low density, was Nanog expression reduced (Figure S2E) . This suggested that autocrine signaling stimulating SMAD2/3 is operative in these cells. Nodal appears to be the factor most probably mediating this effect, because the ActA gene is not expressed in EpiSCs, in contrast to hESCs (Figure 2H) . To confirm this notion, we silenced Nodal expression, via RNA interference, and found that it resulted in Nanog downregulation and EpiSC differentiation ( Figure S2F ). Interestingly, Nodal knockdown appeared to affect terminal SMAD3 rather than SMAD2 phosphorylation, suggesting selective effector usage by autocrine Nodal ( Figure 2I , right). In contrast, when cells were grown in conditioned medium (which contains ActA) or unconditioned medium plus recombinant ActA, the knockdown phenotype was at least partially rescued, demonstrating that paracrine factors can substitute for autocrine Nodal (Figure 2I , left; Figure S2F ). Taken together, these findings indicate that SMAD2/3 signaling directly controls Nanog expression in EpiSCs.
FGF Signaling Inhibits Neural Commitment in EpiSCs
We next investigated how FGF2 may support EpiSC self-renewal. In MEF-dependent culture, FGF2 induces ActA secretion from the feeder layer, which may overshadow its direct effects on EpiSCs ( Figure S2A ). Alternatively, E3 EpiSCs could also be maintained in an undifferentiated state in defined N2B27 medium supplemented with FGF2 alone ( Figure 3A ; Yao et al., 2006) . Although the rates of spontaneous differentiation, particularly with lines T9 and E5, appeared to be somewhat higher than in MEF-conditioned medium, N2B27 medium allowed assessment of FGF-mediated effects over the short term.
To test whether FGF2/ERK signaling enhances EpiSC survival, a cell attachment test was performed. Addition of a ROCK inhibitor was found to increase survival by about 5-fold (Watanabe et al., 2007) . However, FGF2 addition also significantly enhanced attachment/survival after single-cell/small-clump dissociation, which EpiSCs do not tolerate well, and FGF pathway inhibition appeared to reduce cell survival to some extent ( Figure 3B ). To assess whether FGF signaling also stimulates cell proliferation, cell growth was examined. No significant difference between the numbers of cells grown with FGF2 versus those grown without FGF was observed, suggesting that FGF2 supplementation has no effect on cell proliferation in EpiSCs ( Figure 3C ).
To test effects over a longer period, we exposed EpiSCs to FGF/ERK inhibitors ''SU'' or ''PD'' (see Figure S1 ) continuously. In line with the data in Figure 3B , we noticed increased cell death and also differentiation in the presence of FGF/ERK inhibitors. Global transcription profiles were recorded at passage 2 to investigate differential gene expression in comparison with FGF2-treated control cells. Gene ontology analysis revealed that the gene set upregulated with SU and PD was highly enriched in terms associated with neural development, raising the possibility that FGF signaling in EpiSCs may act to inhibit differentiation into that lineage ( Figure S3A ). Of note is that inhibition of neural induction by FGF signaling has also been observed in hESCs. In particular, PAX6 induction appeared to be repressed by the addition of FGF2 to the medium (Greber et al., 2008) . We have reproduced these data with a different hESC line, HuES6 ( Figure S3B ).
We therefore assessed whether a similar effect on the induction of early neuroectodermal genes occurs in EpiSCs. When neuroectodermal differentiation was permitted by inhibiting SMAD2/3 signaling (to suppress Nanog) in the presence of FGF2, the markers Sox2 and Sox1 were indeed clearly induced. However, without FGF2 addition, Sox2 and Sox1 upregulation was at least equally pronounced and, strikingly, Pax6 induction was significantly stronger ( Figure 3D ). A similar pattern was observed with inhibitors to completely inactivate FGF/ERK signaling ( Figure S3C ). The preferred induction of Pax6 in the absence of FGF signaling was confirmed at the protein level via immunocytochemistry ( Figure 3E ). To assess whether terminal differentiation is also affected, induced cultures were left untreated for 2 more days and then stained for the neuronal marker b-III-Tubulin. Neurons readily formed after induction with SB + FGF2 or SB + PD. Their numbers, however, appeared to be higher after SB + PD pretreatment. Similar results were obtained with SU to suppress FGF signaling (not shown). Moreover, many neurons formed even upon continuous SB + PD treatment and, again, the numbers were higher than those after exposure to SB + FGF2 ( Figure S3E ). According to gene expression analysis, the difference in neuronal marker gene expression was severalfold ( Figure S3F ). In conclusion, FGF signaling inhibits, but does not fully block, neuroectodermal induction in EpiSCs, similar to the situation in hESCs ( Figure S3B ).
FGF Signaling Does not Support Nanog Expression in EpiSCs
The above FGF-mediated effects may be beneficial for hESC/ EpiSC maintenance, but they are not strictly associated with promoting self-renewal. For any bona fide self-renewal factor, one may postulate a positive effect on the transcription factor network controlling self-renewal and pluripotency. Indeed, there are indications that this also applies to FGF2 signaling in hESCs and, interestingly, OCT4 has been suggested to control FGF2 expression (data in Boyer et al., 2005) . In contrast, it appears that Fgf2 is not expressed in EpiSCs ( Figure 4A ). By using ChIP-qPCR, we confirmed the binding of OCT4 to the FGF2 gene in human ESCs. However, there was no enrichment in the orthologous region in EpiSCs ( Figure 4B ; Figure S4A ).
It has been noted that in hESCs, not only does SMAD2/3 support NANOG expression, but so does FGF signaling, whereas the mechanism linking NANOG expression and FGF signaling is poorly understood (data in Greber et al., 2007 Greber et al., , 2008 Wang et al., 2009) . This was confirmed with independent batches of hESCs via short-term FGF/ERK inhibition and two sets of NANOG qPCR primers. Irrespective of the FGF/ERK cascade inhibitor or PCR amplicon used, FGF/ERK inhibition caused a 50% decrease in NANOG mRNA levels within 12 hr. The effect of SMAD2/3 inhibition was stronger (85% decrease), but additional FGF receptor blockage caused a further drop in NANOG expression, indicating cooperation between the two pathways ( Figure 4C ). The dependence of NANOG expression on FGF/ERK signaling in hESCs was also confirmed at the protein level ( Figure 4E ). In stark contrast, no effect on Nanog expression was observed in similar experiments with EpiSCs (Figures 4D and 4F ; Figure S4B ). This was also confirmed with an independent EpiSC line ( Figure S4B ). We conclude that FGF signaling in cooperation with SMAD2/3 signaling mediates NANOG expression in hESCs, thereby actively promoting selfrenewal. However, EpiSCs appear to respond only to SMAD2/ 3 activation.
Dedifferentiation of EpiSCs to an ESC-like State
Is Cooperatively Promoted by FGF/ERK Inhibition, GSK3b Inactivation, and LIF/STAT3 Stimulation In addition to self-renewing or differentiating along somatic cell lineages, EpiSCs have another option in culture: they can revert back to an ESC-like state. This was first shown by Klf4 overexpression ). However, data in a recent report suggest that switching to stringent mESC culture conditions alone supports this reversion (in Hanna et al., 2009 ). Interestingly, this medium contains-in addition to LIF and a GSK3b inhibitor (''CH'')-a MEK inhibitor to inactivate the FGF/ERK 
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Roles of SMAD2/3 and FGF Signaling in EpiSCs cascade (PD, see Figure S1 ). We hypothesized that this may in turn suggest another role for FGF/ERK signaling: to stabilize the epiblast state by preventing dedifferentiation.
To assess this, E3 EpiSCs were seeded onto MEFs as small clumps and treated separately with PD, CH, and LIF. Cells treated with CH showed overt differentiation, whereas cultures treated with PD or LIF still formed flat EpiSC-like colonies. However, for each condition, small dome-shaped colonies were also seen to emerge within 3 days. Interestingly, when added in combination, many more-about one third of the total-demarcated ESC-like colonies had formed ( Figure 5A ). Splitting these PD/CH/LIF-treated cultures via single-cell dissociation enriched for these cells, whereas differentiated ones appeared to become outcompeted. After 1 or 2 passages, the cultures were homogeneous and morphologically indistinguishable from those of mESCs ( Figure 5A ). The new cells, termed E3R, could be grown on gelatin and stained strongly positive for alkaline phosphatase, in contrast to E3 EpiSCs (Figures 5A and 5B) . Via markers to distinguish mESCs and EpiSCs, these cells were found to display a typical mESC profile ( Figure 5C ). Like mESCs, E3R cells showed activity of the distal Oct4 enhancer, whereas parental E3 EpiSCs preferentially used the epiblast-specific proximal enhancer ( Figure 5D ; Yeom et al., 1996) . EpiSCs were sensitive to inhibition of SMAD2/3, whereas E3R and ESCs were not ( Figure 5E ). In contrast, E3R and ESCs displayed downregulation of ESC markers upon LIF/STAT3 inhibition, whereas EpiSCs showed no response ( Figure 5F ). Global gene expression analysis revealed that E3R cells clustered together with ESCs but not with parental EpiSCs ( Figure 5G ). Finally, upon combination with preimplantation embryos, E3R cells gave rise to high-contribution coat color chimeras, followed by germline transmission, which demonstrates mESC-like pluripotency ( Figure 5H) .
We also performed similar experiments to revert T9 EpiSCs (mostly 129 inbred background). The efficiency of reversion to ESC-like colonies was found to be substantially lower than that with E3 EpiSCs, but the reverted cells were robust in the sense that they could be maintained with LIF alone (Figures S5A-S5C ). We could also revert a third line, E5, or replace PD by an alternative FGF inhibitor (SU), suggesting that the procedure itself is robust ( Figures S5D and S5E) . In contrast to reverted T9 EpiSCs, E3R cells (hybrid background) required the continuous presence of PD, CH, and LIF to maintain the ESC state, consistent with observations with ESCs from so-called nonpermissive backgrounds ( Figure S5F ; Hanna et al., 2009) . Taken together, these findings suggest that EpiSCs can be reverted to an ESClike state at variable efficiency, simply by switching to stringent mouse ESC culture conditions.
Klf2 Is a Repressed Target of FGF Signaling in EpiSCs and ESCs
Because reversion of the E3 EpiSC line was very efficient, we thought it should be possible to track the induction of ESCspecific gene expression after treatment with different molecules. First, we harvested samples from bulk cultures treated with PD, CH, and LIF alone or in combination for 3 days-i.e., when ESC-like colonies first become apparent ( Figure 5A ). The induction of ESC-specific markers was indeed readily detectable. At the same time, markers for somatic and extraembryonic differentiation were found to be upregulated. This was mostly attributable to the addition of CH, because EpiSCs with LIF alone did not exhibit much differentiation (Figures 5A and 6A) . In contrast, the three molecules appeared to cooperate in the induction of mESC-specific markers, consistent with the increase in ESC-like colony numbers when the molecules were used in combination ( Figures 5A and 6A ). To quantify this cooperativity and to confirm that FGF/ERK inhibition also makes a contribution to the reversion of EpiSCs, ESC-like alkaline phosphatase-positive colonies were scored after 4 days of treatment Figure S4 for additional data.
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Roles of SMAD2/3 and FGF Signaling in EpiSCs with various media. Irrespective of the presence or absence of CH or LIF, PD treatment significantly enhanced reversion efficiencies. In contrast, FGF treatment greatly diminished the formation of ESC-like colonies, suggesting that FGF/ERK signaling indeed serves to prevent the dedifferentiation of EpiSCs ( Figure S6 ).
To determine whether the three-molecule-mediated reversion of EpiSCs comprises an inductive rather than a selective process, we performed short-term treatment for just 3 hr and determined the effect on downstream gene expression. Alteration in the expression of direct target genes of the respective pathways was observed: Egr1, downregulated with PD treatment; T, upregulated with CH treatment (Arnold et al., 2000) ; and Socs3, upregulated with LIF treatment (Table S3) . Strikingly, Klf2, a direct reprogramming factor (Nakagawa et al., 2008) , turned out to be induced by FGF/ERK inhibition but its upregulation was even stronger with PD/CH/LIF treatment ( Figure 6B ; Table S3 ). We performed the same treatments for two more time points and assessed the results by array and real-time analysis to confirm these findings. As shown in Figure 6C , Klf2-but not Klf4-became gradually induced over time. Intriguingly, the molecules appeared to synergize/cooperate in activating Klf2: FGF/ERK inhibition had an immediate-early effect, whereas CH treatment accounted for activation at later time points (Figures 6A and 6C; Tables S3 and S4) . Considering that Klf2 can substitute for Klf4 in direct reprogramming (Nakagawa et al., 2008) and that Klf4 or Klf2 overexpression is sufficient to revert EpiSCs to an ESC-like state Hall et al., 2009) , these data suggest that there may be an inductive mechanism regulating medium switch-based EpiSC reversion. To substantiate this hypothesis, we silenced Klf2 in EpiSCs by using RNA interference, which did not interfere with EpiSC self-renewal, as expected. Compared with controls, the Klf2 knockdown cells indeed reverted at substantially lower efficiency ( Figure 6D ). Hence, induction of Klf2 by the PD/CH/LIF cocktail correlates with ESC-like colony formation efficiency and, moreover, endogenous Klf2 is required for PD/CH/LIFmediated EpiSC reversion.
The fact that EpiSCs could be reverted to ESC-like cells by manipulating the activities of three signaling pathways prompted us to ask whether the opposite treatments would support the formation of epiblast cells from ESCs. This question was also motivated by the fact that LIF treatment did not lead to induction of Klf4 expression in EpiSCs, although activation of this pathway has been found to sustain Klf4 expression in mESCs ( Figure 6C ; Hall et al., 2009; Niwa et al., 2009) . With an emphasis on the LIF/ STAT3 and FGF/ERK pathways, we therefore carried out the complementary stimulation/inhibition experiments: To exclude autocrine effects, mESCs were grown in LIF plus PD and then treated for 12 hr with (1) FGF + LIF, (2) a JAK inhibitor + PD, and (3) a JAK inhibitor + FGF. Consistent with the finding that suppression of FGF/ERK signaling leads to Klf2 induction in EpiSCs, FGF/ERK stimulation in mESCs resulted in moderate but significant Klf2 suppression ( Figure 7A ; Table S5 ). In 
Roles of SMAD2/3 and FGF Signaling in EpiSCs comparison, LIF stimulation did not lead to Klf4 induction in EpiSCs ( Figure 6C ), but inhibition of the LIF/STAT3 pathway led to significant Klf4 repression in mESCs ( Figure 7A ). The same treatments were applied to cultures on feeder layerswhich are compatible with both ESC and EpiSC growth. Both FGF treatment and inhibition of LIF/STAT3 signaling led to an EpiSC-like colony morphology-i.e., flattening of the mESC colonies-within 2 days, whereas combined treatment produced this effect even earlier ( Figure 7B and not shown). Realtime PCR analysis revealed again that Klf2 suppression correlated with FGF/ERK stimulation and that Klf4 suppression correlated with LIF/STAT3 inhibition. Consistent with the above morphological changes, LIF/STAT3 inhibition led to a strong induction of the expression of epiblast marker Fgf5, whereas FGF/ERK stimulation also contributed to this effect, resulting in highest Fgf5 levels with combined treatment (Figures 7B and  7C ). In conclusion, ES and epiblast cell states can be converted into each other in vitro by manipulating the activities of a set of signaling pathways. 
DISCUSSION
NANOG is a direct downstream target of SMAD2/3 signaling in hESCs. However, several (putative) binding sites in the Nanog promoter are not well conserved in the mouse (Greber et al., 2008; Vallier et al., 2009a; Xu et al., 2008) . This led to speculation that there may be a species-specific difference in regulatory pathways (in Greber et al., 2008) . However, one putative binding site, which has been overlooked in two independent studies, is present in the mouse Nanog promoter several bp upstream of the known SOX-OCT bipartite motif. Our data suggest that this site is functional in EpiSCs and that SMAD2/3 signaling occurs upstream of Nanog in EpiSCs, as in hESCs (Figures 7D and 2 ). SMAD2/3 signaling is likely to be a key mechanism in the self-renewal of EpiSCs, because inactivation of the pathway promotes neuroectodermal differentiation in both hESCs and EpiSCs, which can be prevented by constitutive Nanog expression (Greber et al., 2008; Smith et al., 2008; Tesar et al., 2007; Vallier et al., 2009a) . Nodal is likely to be the major autocrine factor responsible for activating the SMAD2/3 pathway, which acts to maintain the pluripotent epiblast cell state, consistent with findings in vivo (Figure 2 ; Camus et al., 2006) .
We find that FGF2 addition has an inhibitory effect on neuroectodermal induction-particularly on PAX6/Pax6 expression-in both hESCs and EpiSCs, an effect that is nota bene totally distinct from the well-known role of FGF2 in supporting the selfrenewal of neural stem cells (Figures 3D and 3E ; Figure S3 ; Greber et al., 2008) . Hence, the efficiency of neural induction in EpiSCs can be enhanced by inhibiting both SMAD2/3 and FGF/ERK signaling. In hESCs, but apparently not in EpiSCs, additional suppression of endogenous BMP signaling may be required to increase the differentiation specificity and fully reveal the inhibitory effect of FGF/ERK signaling ( Figure S3B and associated text, Figure S3D ). FGF-mediated inhibition of neuroectodermal gene expression in hESCs and EpiSCs can contribute to the maintenance of the undifferentiated state ( Figure 7D ). However, FGF2 supplementation of culture media cannot fully block neuroectodermal commitment, a fact that may help address the discrepancy between our conclusions and those drawn by others (Vallier et al., 2009a (Vallier et al., , 2009b ; Figure S3B and associated text).
FGF/ERK signaling also plays a more positively acting role in hESCs: namely to support NANOG expression (Figure 4 ). The precise mechanism underlying this aspect of FGF2 action is not understood. Nonetheless, we believe that the previously recognized cooperation between FGF/ERK and SMAD2/3 pathways in supporting hESC self-renewal (Vallier et al., 2005) culminates in the activation of NANOG as a shared target. However, the effect of SMAD2/3 signaling on NANOG expression in hESCs is dominant, so that the contribution of FGF2 is overshadowed and becomes apparent only in defined media lacking any SMAD2/3-stimulating factors. Interestingly, the FGF2 gene appears to be directly controlled by OCT4, suggesting the presence of an autocrine loop that helps to sustain selfrenewal in hESCs, which may involve all pleiotropic downstream effects of FGF2 signaling described to date (Figure 4 ; Bendall et al., 2007; Boyer et al., 2005; Eiselleova et al., 2009; Greber et al., 2007; Li et al., 2007; Ludwig et al., 2006) . In contrast, FGF2 signaling does not seem to actively promote self-renewal via Nanog expression in EpiSCs, according to our assays with feeder-free conditions. The situation is different when EpiSCs are grown on MEFs, because FGF2 enhances the secretion of ActA from these cells, thus acting indirectly through another pathway. However, our data suggest that the active and direct role of FGF2 signaling in supporting self-renewal through NANOG is specific to human ESCs and not shared with EpiSCs. The shear existence of a hESC-specific feature is, in principle, not very surprising considering that hESCs are equivalent to neither mESCs nor to EpiSCs (they appear to share features with both cell types, see above) and that there are notable differences in early development between mouse and human (Larsen, 2001; Nagy et al., 2003) . We cannot rule out the possibility that FGF signaling may activate the expression of target genes other than Nanog to sustain self-renewal in EpiSCs.
EpiSCs can be reverted back to an ESC-like state in vitro by the overexpression of Klf4 ). This is a very perspicuous finding, because (1) Klf4 is one of Yamanaka's reprogramming factors (Takahashi and Yamanaka, 2006) , (2) KLF4 is an integral component of the mESC self-renewal network (Chen et al., 2008; Jiang et al., 2008) , and (3) EpiSCs virtually do not express Klf4. Recent data by Hanna et al. (2009) suggested that a stringent mESC medium alone could be sufficient to revert EpiSCs to an ESC-like state. It is probable that a MEF feeder layer facilitates this process, because it is
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Roles of SMAD2/3 and FGF Signaling in EpiSCs a substrate supporting the growth of both ESCs and EpiSCs. We have reverted several EpiSC lines via PD/CH/LIF-containing medium and demonstrate that the resultant cells exhibit ESC-specific properties and developmental potential. Reversion efficiencies with the hybrid E3 line were sufficiently high to investigate the medium-induced effects on gene expression. Irrespective of the mechanism (direct versus indirect), FGF/ERK suppression, GSK3b inhibition, and LIF/STAT3 activation appeared to cooperate in reverting the EpiSCs. GSK3b inhibition selected against the epiblast state by inducing (mesendodermal) differentiation in many, but not all, cells, consistent with the prominent role of WNT/b-catenin signaling in mammalian gastrulation ( Figure 7D ; Murry and Keller, 2008; Sumi et al., 2008) . LIF appeared to make a contribution at later stages, perhaps by stabilizing the reverted state, because LIF treatment alone did not immediately induce the expression of any ESC-specific genes but was most productive over the long term ( Figure 6A ). However, cooperation between the three molecules was most evident in the induction of Klf2, whereas FGF/ERK suppression had the strongest immediate-early effect on Klf2 expression ( Figure 7D ). Klf2 can substitute for Klf4 in direct reprogramming experiments, and Klf4 or Klf2 overexpression enables EpiSC reversion Hall et al., 2009; Nakagawa et al., 2008) . Moreover, knockdown of Klf2 in EpiSCs impaired reversion efficiencies ( Figure 6D ). Given that ESCs tolerate Klf2 silencing , these data therefore suggest that medium switch-based reversion of EpiSCs may at least partly constitute an inductive process involving KLF2. This would not be based on replacing the function of a reprogramming factor with small molecules but on inducing its endogenous expression by manipulating the activities of signaling pathways.
Krü ppel-like transcription factors (Klfs) are upstream regulators of Nanog expression in ESCs . Because EpiSCs express much lower levels of Klf2 and Klf4 but rather depend on SMAD2/3 signaling to drive Nanog expression, it appears that a transition from the ES to the epiblast cell state must also involve a switch in Nanog regulation. The effect of FGF/ERK signaling on repressing Klf2 was consistent in EpiSCs and mESCs. In contrast, LIF stimulation had a positive effect on Klf4 expression only in ESCs. Consequently, LIF/STAT3 suppression and FGF/ERK stimulation had a cooperative effect in diminishing both Klfs in ESCs ( Figure 7D) . It is quite possible that withdrawal of the GSK3b inhibitor is also a contributing factor (data not shown). The levels of Fgf5, a marker for the epiblast state, were also increased in a cooperative way. Interestingly, it has been revealed that the Fgf5 gene is a repressed direct target of Klfs in mESCs , underscoring the importance of downregulation of Klfs during the ES-Epi cell transition.
The model in Figure 7D suggests that there is an equilibrium between the ES and epiblast cell states, the precise position of which is dictated by the culture conditions. This may be more evident for so-called nonpermissive mouse strains than for 129 inbred cells (Hanna et al., 2009) . A recent report by Bao et al. (2009) describing the generation of mESC-like cells from EpiSCs grown under low-stringency mESC culture conditions supports the equilibrium concept. Our data confirm that LIF treatment alone can give rise to ESC-like colonies. However, EpiSC reversion efficiencies were significantly higher when blocking FGF/ ERK and GSK3b in addition, underscoring the idea of cooperation among the three molecules ( Figure 5A ; Figure S6 ). The model further implies that somatic cell lineage commitment always commences from the epiblast and not from the ES cell state, in accordance with the in vivo situation. Work by Kunath et al. (2007) revealed that Fgf4 À/À or Erk2 À/À ESCs are deficient in somatic cell lineage commitment. According to the model in Figure 7D , such cells could become stuck halfway between the ES and epiblast cell states. Finally, the model does not question data by Ying et al. (2003) suggesting that FGF/ERK signaling is required for neuroectodermal induction in ESCs, as this differentiation process appears to be composed of at least two steps (J.S., unpublished data): the first step (ES-Epi) would be promoted by FGF/ERK, whereas the second (Epi-Neuro) would be inhibited, but not blocked, by FGF/ERK signaling ( Figure 7D ). Taken together, our data are consistent with published findings and extend the current model of cell fate decisions concerning the epiblast cell state (Tesar et al., 2007) by elucidating the roles of FGF/ERK signaling.
EXPERIMENTAL PROCEDURES
Cell Culture Hybrid E3 EpiSCs were derived from day 5.5 epiblasts generated by mating homozygous GOF18-EGFP male mice (Yoshimizu et al., 1999 ; C57Bl/6 and DBA/2 background) with 129/Sv female mice. The activity of the Oct4-GFP transgene was gradually silenced over time for unknown reasons, whereas that of endogenous Oct4 was stable. After initial mechanical passaging on MEFs (strain CF1), cells were split with collagenase IV. KSR medium contained 20% Knockout Serum Replacement and was supplemented with 5 ng/ml FGF2 to yield ''unconditioned medium'' (UM; Amit et al., 2004) . For feederfree culture, cells were adapted to grow in MEF-conditioned medium (CM; Xu et al., 2001 ) on FCS-coated dishes. Some experiments were carried out in defined N2B27 medium (Yao et al., 2006) . Human ESCs (H1, H9, HuES6; Cowan et al., 2004; Thomson et al., 1998) were treated in N2B27 medium. Mouse ESCs or reverted EpiSCs were grown on MEFs or on gelatin-coated plates in KSR medium wherein the specified factors were added. Reverted E3 EpiSCs displayed reactivation of the Oct4-GFP transgene.
RT-qPCR and Microarray Analysis
Cells for RNA isolation were usually lysed directly in the culture wells. Reverse transcription was done with MMLV enzyme (USB) and oligo dT 15 priming. qPCR was carried out with SYBR Green mix (ABI). All qPCR primers were validated with respect to efficiency and specificity (Table S6) . Calculations were based on the DDCt method employing two housekeeping genes for normalization. cRNA samples for global gene expression analyses were prepared with the linear TotalPrep RNA Amplification Kit (Ambion). Hybridizations on mouse-8 V2 chips (Illumina) were carried out as recommended by the manufacturer. Data analysis was done in BeadStudio and MS Excel.
Immunoblotting and ChIP-qPCR Cells for western blotting were rapidly harvested by scraping in culture medium, pelleted, and lysed on ice, if necessary, to preserve the phosphorylation status of the proteins. Electrophoresis, blotting, and antibody incubations were carried out according to standard procedures.
For ChIP-qPCR, we adopted and scaled down a published protocol (Lee et al., 2006) . Fold enrichment was calculated with the DDCt method, by normalizing Ct values against two (human) or three (mouse) independent genomic reference loci and comparing them to the input sample set to 1-fold.
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